FDA 评估减肥药 Ozempic 的潜在自杀风险。 FDA evaluates potential suicide risk with weight-loss drugs Ozempic.

减肥药 Ozempic 和 Wegovy 含有活性成分索马鲁肽，目前正在接受 FDA 评估其是否存在自杀风险，此前有报道称服用这两种药物会导致自杀念头和抑郁症。 Weight-loss drugs Ozempic and Wegovy, containing active ingredient semaglutide, are under FDA evaluation for potential suicide risk, following reports of suicidal thoughts and depression linked to their use. 尽管 FDA 目前正在调查，但欧洲药品管理局已经得出结论，没有证据支持 GLP-1 受体激动剂（包括索马鲁肽）与自杀想法或行为之间存在因果关系。 While the FDA is currently investigating, European Medicines Agency has concluded that no evidence supports a causal association between GLP-1 receptor agonists, which include semaglutide, and suicidal thoughts or actions.

April 15, 2024

7 文章